Synthesis, coordination properties and biological activity of vanadium complexes with hydrazone Schiff base ligands. (15th July 2020)

• Record Type: Journal Article
• Authors: Szklarzewicz, Janusz; Jurowska, Anna; Matoga, Dariusz; Kruczała, Krzysztof; Kazek, Grzegorz; Mordyl, Barbara; Sapa, Jacek; Papież, Monika
• Is Part Of: Polyhedron. Volume 185(2020)
• Publication Date: 2020-07-15
• Subjects: Vanadium -- Schiff base -- Spectroscopy -- Thermogravimetric measurements -- Biological activity; Chemistry, Inorganic -- Periodicals; Chimie inorganique -- Périodiques; Organometaalverbindingen; Anorganische chemie; 546.05
• DOI: 10.1016/j.poly.2020.114589
• Languages: English
• ISSNs: 0277-5387

Abstract

Graphical abstract: Vanadium complexes with keto- or enol- form of hydrazide, the keto : enol form ratio was determined by EPR spectroscopy. The biological activity (inhibition of human phosphatases, cytotoxity and glucose uptake in myocytes and adipocytes) of the complexes was tested in vitro . Abstract: Seventeen complexes of vanadium (III-V) with hydrazido-hydrazone Schiff bases, formed from 5-bromosalicylaldehyde and different hydrazides, are described and characterized by elemental analysis, IR, UV–Vis (in solution and as reflectance spectra) and EPR spectroscopy, cyclic voltammetry and thermogravimetric measurements. The nonoxido complexes show reversible oxidation to V(V), while oxido ones only irreversible processes. The thermogravimetric measurements indicate that Schiff base is released as its components in two separated steps. The detailed EPR measurements show distorted octahedral geometry for oxido complexes with presence of two oxidovanadium(IV) centers attributed to complexes with keto- or enol- form of hydrazide, the ratio of keto : enol form was determined. The biological activity, such as inhibition of human phosphatases (PTP1B, SHP1, SHP2, LAR and CD45), cytotoxicity and glucose uptake in myocytes (C2C12) and adipocytes (3 T3-L1) of selected complexes was tested. The obtained results indicate that the strength of tyrosine phosphatases inhibition of tested complexes does not determine the strength of their antidiabetic activity demonstrated in the glucose transport to myocytes and adipocytes. This last effectiveness is much higher than for VOSO4 and BMOV.